PacBio (PACB)
Builds HiFi sequencing platforms centered on Revio, Vega, and consumables.
Something off on this page? Send us feedback.
Sells long-read sequencing instruments, consumables, software, and services for genomic analysis. Consumables are the largest revenue category, and the business is refocused on HiFi long-read adoption after selling selected short-read assets.
Sells Revio and Vega sequencing systems, SMRT Cells, chemistry, sample-prep kits, software, and services built around SMRT and HiFi long-read sequencing. Customers include research institutions, service labs, public health groups, pharmaceutical companies, and agriculture users.
Revenue is reported as a single genetic-analysis platform segment across instruments, consumables, and service or other offerings. Sales span the Americas, EMEA, and Asia-Pacific, with the United States forming most of the Americas line.
Execution depends on expanding the installed base, repeat consumables use, and clinical-research adoption of HiFi sequencing. Products are generally research-use-only unless regulatory status changes, and many customers buy through purchase orders rather than long-term volume commitments.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Target | Target: — | Target: $1.35 |
| Apr 14, 2026 | Barclays | Reiterate | Rating: —Target: $1.50 | Target: $1 |
| Mar 6, 2026 | Barclays | Downgrade | ||
| Nov 11, 2024 | UBS | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $236.9M · Total debt $706.1M · Total assets $751.9M · Shareholders' equity −$33.2M
- Revenue
- $39.0M
- Operating income
- −$44.6M
- Net income
- −$44.7M
No dividends on record.
| Institutions | 62.33% | 193.74M shares | |
|---|---|---|---|
| 229 holders · as of Jun 30, 2026 | |||
| Insiders | 1.93% | 5.99M shares | |
| 6 holders · as of Apr 10, 2026 | |||
| Other | 35.74% | 111.09M shares | |
| remainder | |||
310.83M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 10.40% | 32.34M | as of Jun 30, 2026 |
Ark Investment Management LLCInstitution | 9.58% | 29.78M | as of Jun 30, 2026 |
SoftBank Group Corp.Institution | 6.58% | 20.45M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.31% | 13.40M | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 2.45% | 7.61M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Mark van Oene | officer: See Remarks | −26,911 | $1.13 |
| Apr 1, 2026 | James R. II Gibson | officer: See Remarks | −88,185 | $1.37 |
| Mar 3, 2026 | Michele Farmer | officer: See Remarks | −2,979 | $1.51 |
| Mar 3, 2026 | Mark van Oene | officer: See Remarks | −6,504 | $1.51 |
| Mar 3, 2026 | Christian O. Henry | officer: See Remarks | −12,497 | $1.51 |
- Illumina
Dominant short-read and emerging long-range sequencing rival
- Onterris
Closest native long-read platform rival
- Thermo Fisher Scientific
Clinical targeted NGS workflow competitor
- QIAGEN
NGS library-prep and targeted-panel workflow rival
- 10x Genomics
Single-cell and spatial workflow competitor
- Bionano Genomics
Structural-variation platform adjacent to long-read use cases
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| PacBio | $1.46 | +6.99% | $422.4M | — | — | 2.7 | −1.9% |
| Illumina | $246.20 | +3.09% | $36.13B | 44.6 | 43.2 | 8.0 | +9.4% |
| Onterris | $16.87 | −3.49% | $631.7M | — | 81.9 | 0.8 | −20.4% |
| Thermo Fisher Scientific | $659.68 | +0.14% | $244.81B | 35.4 | 25.2 | 5.3 | +10.5% |
| QIAGEN | $43.79 | −2.21% | $9.24B | 23.0 | 17.5 | 4.4 | +0.3% |
| 10x Genomics | $81.71 | +3.30% | $10.04B | — | — | 16.3 | −12.7% |
| Bionano Genomics | $1.81 | −1.37% | $21.0M | — | — | 0.7 | +21.4% |
| Median | 35.4 | 34.2 | 4.8 | +4.9% |